GLIX1 named FDA orphan drug as potential malignant glioma therapy
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to GLIX1, a cancer treatment now in the preclinical stages of development, as…
Glioma
Glioma overview
Gliomas are a group of brain tumors that arise from glial cells, a type of support cell of the central nervous system, or CNS, which comprises the brain and spinal cord. They make up about one-quarter of all tumors that start in the brain (primary brain tumors), occurring in about 6.6 per 100,000 people every year. They also account for more than 80% of all malignant, or cancerous, brain tumors.
Read moreGlioma treatment
Treatment for gliomas, a diverse group of tumors that form in the brain and spinal cord, can involve a variety of approaches, including surgery, radiation therapy, and chemotherapy, as well as a range of supportive treatments.
Read moreNews
Reyobiq trial for high-grade pediatric glioma approved by FDA
Reyobiq (Rhenium Re186 Obisbemeda), an experimental radiation therapy being developed by Plus Therapeutics, has been cleared by the U.S. Food and Drug Administration (FDA)…
Unusual glioma tumor case shows need for molecular testing
A young girl with an unusual form of low-grade glioma, a type of brain tumor, responded well to standard chemotherapy, emphasizing the value of…
Glioblastoma treatment lucicebtide well tolerated in clinical trial
Data from a clinical trial show the experimental treatment lucicebtide has so far been well tolerated in people with glioblastoma, an aggressive type of…
1st patient dosed in trial of PRMT5 inhibitor for glioblastoma
The first participant has been dosed in a Phase 1/2 trial investigating TNG456, a PRMT5 inhibitor to treat people with advanced solid tumors with MTAP…
BCB-276 cell therapy for pediatric brain cancer gets new FDA status
BCB-276, an experimental cell therapy that Brainchild Bio is developing for diffuse intrinsic pontine glioma (DIPG), has been named a regenerative medicine advanced…
